0 809

Cited 45 times in

Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer

DC Field Value Language
dc.contributor.author김형일-
dc.contributor.author김효송-
dc.contributor.author노성훈-
dc.contributor.author라선영-
dc.contributor.author박형순-
dc.contributor.author안지영-
dc.contributor.author정민규-
dc.contributor.author정재호-
dc.contributor.author정현철-
dc.contributor.author형우진-
dc.date.accessioned2016-02-04T10:54:38Z-
dc.date.available2016-02-04T10:54:38Z-
dc.date.issued2015-
dc.identifier.issn1068-9265-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/139248-
dc.description.abstractBACKGROUND: Adjuvant chemotherapy improves survival in patients with gastric cancer. However, the relationship between the timing of adjuvant chemotherapy and survival has not been investigated. METHODS: Patients with D2-resected stage 2 and 3 gastric cancer that received adjuvant chemotherapy from 2005 to 2011 at Yonsei University Health System were included. The patients were grouped according to intervals between surgery and adjuvant chemotherapy. RESULTS: Among 840 patients, the interval from surgery to the start of adjuvant therapy was less than 4 weeks in 337 (40.1 %) patients (early group), 4-8 weeks in 467 (55.6 %) patients (intermediate group), and more than 8 weeks in 36 (4.3 %) patients (late group). The 5-year RFS was 55.7 % in the early group, 54.4 % in the intermediate group, and 43.6 % in the late group (p = 0.076). The corresponding 5-year OS rates were 63.4, 62.8, and 51.7 % (p = 0.037). CONCLUSIONS: There is insufficient evidence to suggest starting adjuvant chemotherapy within 4 weeks after surgery for patients with D2 resected stage 2 and 3 gastric cancer. However, delayed treatment of adjuvant chemotherapy after 8 weeks showed worse survival outcomes than early and intermediate treatment initiation, suggesting that adjuvant chemotherapy should be considered start within 8 weeks after radical resection.-
dc.description.statementOfResponsibilityopen-
dc.format.extent224~231-
dc.relation.isPartOfANNALS OF SURGICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma, Mucinous/drug therapy-
dc.subject.MESHAdenocarcinoma, Mucinous/mortality*-
dc.subject.MESHAdenocarcinoma, Mucinous/pathology-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCarcinoma, Signet Ring Cell/drug therapy-
dc.subject.MESHCarcinoma, Signet Ring Cell/mortality*-
dc.subject.MESHCarcinoma, Signet Ring Cell/pathology-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHNeoplasm Recurrence, Local/drug therapy-
dc.subject.MESHNeoplasm Recurrence, Local/mortality*-
dc.subject.MESHNeoplasm Recurrence, Local/pathology-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHStomach Neoplasms/drug therapy-
dc.subject.MESHStomach Neoplasms/mortality*-
dc.subject.MESHStomach Neoplasms/pathology-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTime Factors-
dc.titleProper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학)-
dc.contributor.googleauthorHyung Soon Park-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorHyoung-Il Kim-
dc.contributor.googleauthorJi Yeong An-
dc.contributor.googleauthorJae-Ho Cheong-
dc.contributor.googleauthorWoo Jin Hyung-
dc.contributor.googleauthorSung Hoon Noh-
dc.contributor.googleauthorYong Il Kim-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorSun Young Rha-
dc.identifier.doi10.1245/s10434-014-3949-2-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01154-
dc.contributor.localIdA01202-
dc.contributor.localIdA01281-
dc.contributor.localIdA03606-
dc.contributor.localIdA03717-
dc.contributor.localIdA03773-
dc.contributor.localIdA04382-
dc.contributor.localIdA01754-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ00179-
dc.identifier.eissn1534-4681-
dc.identifier.pmid25081339-
dc.identifier.urlhttp://link.springer.com/article/10.1245%2Fs10434-014-3949-2-
dc.subject.keywordAdvanced gastric cancer-
dc.subject.keywordTiming of adjuvant chemotherapy-
dc.subject.keywordSurvival-
dc.contributor.alternativeNameKim, Hyoung Il-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNamePark, Hyung Soon-
dc.contributor.alternativeNameAn, Ji Yeong-
dc.contributor.alternativeNameJung, Min Kyu-
dc.contributor.alternativeNameCheong, Jae Ho-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameHyung, Woo Jin-
dc.contributor.affiliatedAuthorKim, Hyoung Il-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.contributor.affiliatedAuthorNoh, Sung Hoon-
dc.contributor.affiliatedAuthorJung, Min Kyu-
dc.contributor.affiliatedAuthorCheong, Jae Ho-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorHyung, Woo Jin-
dc.contributor.affiliatedAuthorPark, Hyung Soon-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsnot free-
dc.citation.volume22-
dc.citation.number1-
dc.citation.startPage224-
dc.citation.endPage231-
dc.identifier.bibliographicCitationANNALS OF SURGICAL ONCOLOGY, Vol.22(1) : 224-231, 2015-
dc.identifier.rimsid45519-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.